Novo Nordisk’s Key Cardiovascular Drug Trial Fails; Shares Plunge as Much as 10% Premarket
A key cardiovascular drug trial at Novo Nordisk failed, while the company’s shares fell as much as 10% in premarket trading.
A key cardiovascular drug trial at Novo Nordisk failed, while the company’s shares fell as much as 10% in premarket trading.